The primary objective of this study is to assess the safety and efficacy of Tranexamic acid
(TXA) in reducing blood loss and transfusion requirements for patients with osteoporotic hip
fractures. In addition to assessing blood loss in these patients, complications associated
with TXA use would be characterized including systemic (pulmonary embolism, deep venous
thrombosis, myocardial infarction, stroke) and surgical site (hematoma, infection) events,
need for re-hospitalization or re-operation and 30 day mortality.